Category: 3. Business

  • Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

    Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer

    Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session

    CAMBRIDGE, Mass., Nov. 4, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the first presentation of patient-reported outcomes data from the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial of zidesamtinib, an investigational ROS1 inhibitor, as well as encore pivotal efficacy and safety data from the ARROS-1 trial, during two poster presentations at the 2025 IASLC ASCO North America Conference on Lung Cancer being held December 5-7, 2025 in Chicago.

    Details of the poster presentations are as follows:

    Title: Patient-Reported Outcomes and Health-Related Quality of Life of TKI Pre-Treated and TKI-naïve Patients with Advanced ROS1-Positive NSCLC Treated with Zidesamtinib: Examination of ARROS-1 Phase 2 Trial Data
    Abstract Number: PP01.41
    Presenting Author: Melissa Laurie, Pharm.D., M.S., M.B.A.1
    Session Date and Time: Saturday, December 6, 2025, 4:00-5:30 p.m. ET

    Title: Zidesamtinib in Patients With Advanced Metastatic ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Tyrosine Kinase Inhibitors (TKI): Pivotal Efficacy and Safety Data From the Phase 1/2 ARROS-1 Trial
    Abstract Number: PP01.32
    Presenting Author: Stephen V. Liu, M.D.2
    Session Date and Time: Saturday, December 6, 2025, 4:00-5:30 p.m. ET

    1 Nuvalent, Inc., Cambridge, MA, USA; 2Georgetown University, Washington, DC, USA

    About Zidesamtinib and the ARROS-1 Phase 1/2 Clinical Trial

    Zidesamtinib is an investigational, novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is designed to remain active in tumors that have developed resistance to currently available ROS1 inhibitors, including tumors with treatment-emergent ROS1 mutations such as G2032R. In addition, zidesamtinib is designed for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with dual TRK/ROS1 inhibitors and to drive deep, durable responses for patients across all lines of therapy. Zidesamtinib has received breakthrough therapy designation for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have been previously treated with 2 or more ROS1 tyrosine kinase inhibitors and orphan drug designation for ROS1-positive NSCLC.

    Zidesamtinib is currently being investigated in the ARROS-1 trial (NCT05118789), a first-in-human Phase 1/2 clinical trial for patients with advanced ROS1-positive NSCLC and other solid tumors. The completed Phase 1 portion enrolled ROS1-positive NSCLC patients who previously received at least one ROS1 TKI, or patients with other ROS1-positive solid tumors who had been previously treated. The Phase 1 portion of the trial was designed to evaluate the overall safety and tolerability of zidesamtinib, with additional objectives including determination of the recommended Phase 2 dose (RP2D), characterization of the pharmacokinetic profile, and evaluation of preliminary anti-tumor activity. The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with advanced ROS1-positive NSCLC. Nuvalent completed its rolling NDA submission for zidesamtinib in TKI pre-treated patients with advanced ROS1-positive NSCLC in the third quarter of 2025 and continues to engage with the U.S. Food and Drug Administration (FDA) on potential opportunities for line-agnostic expansion.

    About Nuvalent
    Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

    SOURCE Nuvalent, Inc.

    Continue Reading

  • CNH Industrial to invest $5 billion in US manufacturing and research

    CNH Industrial to invest $5 billion in US manufacturing and research

    Nov 4 (Reuters) – Farm and construction equipment maker CNH Industrial (CNH.N), opens new tab said on Tuesday it will invest nearly $5 billion over five years into manufacturing and research and development facilities in the United States.

    CNH also said it will stop production at its Burlington, Iowa, assembly plant by the second quarter of 2026, citing declining demand and underutilization.

    Sign up here.

    It said the plant closure would affect about 200 employees.

    The company will report its third-quarter earnings on November 7.

    Reporting by Anshuman Tripathy in Bengaluru; Editing by Alan Barona

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • Entergy, Energy Transfer sign long-term natural gas transportation deal

    Entergy, Energy Transfer sign long-term natural gas transportation deal

    Nov 4 (Reuters) – Utility Entergy’s (ETR.N), opens new tab unit and pipeline firm Energy Transfer (ET.N), opens new tab have signed a 20-year agreement to deliver natural gas to North Louisiana, the companies said on Tuesday.

    The U.S. is poised to see a record surge in power demand this year and in 2026, led by data centers’ outsized energy needs, the U.S. Energy Information Administration estimates.

    Sign up here.

    The companies said the pipeline would supply gas to Entergy’s new plants and serve projects such as Meta’s (META.O), opens new tab data center in Richland Parish.

    Energy Transfer will initially provide 250,000 million British thermal units (MMBtu) per day of transportation service beginning in February 2028 and continuing through January 2048.

    The deal also provides an option to Entergy to expand delivery capacity in the region to meet future energy demand.

    Reporting by Tanay Dhumal in Bengaluru; Editing by Sriraj Kalluvila

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • The Estée Lauder Companies Announces Secondary Offering of Class A Common Stock by Selling Stockholders – The Estée Lauder Companies Inc.

    The Estée Lauder Companies Announces Secondary Offering of Class A Common Stock by Selling Stockholders – The Estée Lauder Companies Inc.

    NEW YORK–(BUSINESS WIRE)–
    The Estée Lauder Companies Inc. (NYSE: EL) today announces that trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) propose to sell 11,301,323 shares of the Company’s Class A Common Stock, par value $.01 per share, through a proposed registered public offering (the “Offering”).

    The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses.

    Based on shares outstanding as of October 23, 2025, following completion of the offering, members of the Lauder family will beneficially own, directly or indirectly, 82% of the outstanding voting power of the Company’s Common Stock. The Selling Stockholders and LAL Family Partners, L.P., an entity beneficially owned by descendants of Leonard A. Lauder, will be subject to a 90-day lock-up agreement with the underwriter.

    J.P. Morgan Securities LLC is acting as the sole underwriter of the Offering.

    The Company has filed an automatically effective shelf registration statement on Form S-3 (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the Offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the accompanying prospectus supplement and other documents the Company has filed with the SEC for more complete information about the Company and the Offering. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering, as well as copies of the final prospectus supplement once available, may be obtained for free on the SEC’s website at www.sec.gov or by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email: [email protected] and [email protected].

    This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

    ELC-F

    Investors: Rainey Mancini

    [email protected]

    Media: Brendan Riley

    [email protected]

    Source: The Estée Lauder Companies Inc.

    Continue Reading

  • Johnson & Johnson reinforces its leadership in hematology at ASH 2025 unveiling new paradigm-shifting research

    RARITAN, NJ, November 4, 2025 – Johnson & Johnson (NYSE: JNJ), a worldwide leader in hematology, today announced more than 46 poster presentations and 10 oral presentations on hematologic malignancies and other blood disorders will be presented at the 67th American Society of Hematology (ASH) Annual Meeting from December 6–9, 2025, in Orlando, Florida. Results will showcase practice-influencing evidence from across the Company’s diverse hematology portfolio and progress towards advancing next-generation therapies.

    “From first in-human molecules to early intervention and regimens with curative potential, our blood cancer portfolio is advancing new options and addressing unmet needs for patients around the globe,” said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. “This year’s data at ASH showcase the depth of our scientific expertise and bold approach to get in front of cancer.”

    “Johnson & Johnson is focused on improving outcomes and extending survival for patients,” said Imran Khan, M.D., Ph.D., Vice President, U.S. Hematology Medical Affairs, Johnson & Johnson Innovative Medicine. “We aim to deliver meaningful benefits for patients and their families—redefining standards of care across multiple myeloma, leukemia and lymphoma, and accelerating progress toward cures.”

    Multiple myeloma studies highlight the potential to improve survival outcomes and advance treatment options in earlier lines:

    CARVYKTI® (ciltacabtagene autoleucel)

    • Clinical benefit of CARVYKTI® in patients with standard-risk relapsed/refractory multiple myeloma from the CARTITUDE-1 and -4 studies (
      Oral #94)
    • Improvements in immune fitness and immune response associated with earlier line use of CARVYKTI® in CARTITUDE-4 (
      Oral #92)

    DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

    • Minimal residual disease dynamics in post-transplant patients with newly diagnosed multiple myeloma who received maintenance therapy with DARZALEX FASPRO® plus lenalidomide versus lenalidomide alone in the AURIGA study (
      Oral #97)
    • Results from a study evaluating cardiac risk factors and adverse events in newly diagnosed amyloid light chain amyloidosis patients treated with DARZALEX FASPRO® plus bortezomib, cyclophosphamide, and dexamethasone from the Phase 2 AQUARIUS study (
      Oral #691)
    • Results from the AQUILA study evaluating DARZALEX FASPRO® monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma, with subgroup analyses based on Mayo 2018/IMWG 2020 risk criteria, cytogenetic features and patient age (
      Oral #372)

    TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv)

    • Presentations from the RedirecTT-1 study, evaluating dual-antigen targeting combination of TALVEY® and TECVAYLI® in patients with relapsed/refractory multiple myeloma and extramedullary disease, highlighting new three-year follow-up Phase 1 results and updated Phase 2 extended follow-up data (
      Oral #698 and
      #701)
    • Updated safety and efficacy data from the Phase 1b MonumenTAL-2 study evaluating TALVEY® in combination with pomalidomide in patients with relapsed/refractory multiple myeloma (
      Poster #2282)
    • First data from the TALISMAN study reporting how in patients with relapsed/refractory multiple myeloma treated with TALVEY® taste changes present and change over time, along with the development and utility of the WETT-SA53 test in measuring taste changes (
      Poster #5821)

    Other Key Multiple Myeloma Studies

    • Updates from the ramantamig (JNJ-79635322) Phase 1 study, including MRD negativity rates, and data supporting how the recommended Phase 2 dose was identified in patients with relapsed/refractory multiple myeloma (
      Poster #4042 and
      #4054)
    • First presentation of preclinical data on JNJ-87562761, a next-generation GPRC5D monoclonal antibody with enhanced effector function, investigating the effectiveness of multiple mechanisms of action for the treatment of relapsed/refractory multiple myeloma (
      Poster #3934)
    • Real-world findings from REVEAL-MM, a U.S. claims-based case-control study evaluating early assessment variables and landmark trends in multiple myeloma (
      Poster #4569)

    Data highlight foundational treatments and next wave of therapies for leukemia and lymphoma:

    IMBRUVICA® (ibrutinib)

    • First presentation in the ASH Plenary Session will feature results from the Phase 3 CLL17 trial comparing fixed-duration IMBRUVICA® plus venetoclax and continuous targeted treatment with IMBRUVICA® for previously untreated chronic lymphocytic leukemia (CLL) (
      Plenary Scientific Session Abstract #1)
    • First results from the Phase 2 TAILOR study, reporting dose and BTK occupancy correlations from a pre-planned exploratory analysis of IMBRUVICA® monotherapy in patients with previously untreated CLL (
      Poster #3301)

    Bleximenib (JNJ-75276617)

    • Updated data from Phase 1b studies evaluating bleximenib (JNJ-75276617), an investigational oral menin inhibitor, as combination therapy for both newly diagnosed and relapsed/refractory patients with acute myeloid leukemia harboring KMT2A or NPM1 alterations (
      Poster #5199 and
      #5200)

    Prizlo-cel (JNJ-90014496)

    • Biomarker correlations with clinical outcomes from a global Phase 1b study of prizlo-cel (JNJ-90014496), an investigational dual-targeting anti-CD20/CD19 CAR T-cell therapy in patients with large B-cell lymphoma (LBCL) (
      Oral #568)

    Hematologic autoantibody disease research:

    An oral presentation and seven poster presentations on warm autoimmune hemolytic anemia (wAIHA) will spotlight the Company’s innovative research addressing the critical need for approved therapies for this rare, life-threatening disease in which autoantibodies cause the premature destruction of red blood cells, resulting in anemia. Observational and qualitative studies demonstrate the profound burden of both the disease and current standard of care treatment options for people living with wAIHA.

    Information on abstracts sponsored by Johnson & Johnson is available on JNJ.com.

    About Multiple Myeloma
    Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.1 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors.2 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease.3 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease.4 People living with multiple myeloma have a 5-year survival rate of 59.8 percent.5 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections.6,7

    About Smoldering Multiple Myeloma
    Smoldering multiple myeloma (SMM) is an asymptomatic intermediate disease state of multiple myeloma characterized by abnormal monoclonal bone marrow plasma cell (BMPC) proliferation and abnormally high levels of circulating M proteins with absence of myeloma-defining events. SMM is associated with a 10 percent annual risk of progressing to multiple myeloma (MM) or a related disorder, but half of patients with high-risk SMM progress to MM and are at risk of developing severe symptoms and organ damage within just two years of diagnosis.

    About Acute Myeloid Leukemia (AML)
    Acute myeloid leukemia is an aggressive, fast-growing blood cancer that originates in the bone marrow and is marked by the uncontrolled proliferation of immature white blood cells known as myeloblasts.8,9 These malignant cells crowd out healthy blood-forming cells, leading to complications such as anemia, infections and bleeding.10 Acute myeloid leukemia progresses rapidly, often requiring immediate treatment after diagnosis.8 It is the most common type of acute leukemia in adults, with a median age of diagnosis around 70 years.7

    Despite treatment advances, acute myeloid leukemia remains associated with poor patient outcomes, particularly in older adults or those with high-risk genetic profiles.11 The five-year survival rate remains the lowest among leukemias, with outcomes especially poor in patients with KMT2Ar or NPM1m where relapse/refractory disease survival can be as short as 2 to 3 months after a second relapse – highlighting a significant unmet medical need.10

    About large B-cell lymphoma
    Large B-cell lymphoma is a type of non-Hodgkin lymphoma (NHL), a blood cancer that originates in the lymphatic system, arising from abnormal B cells, a type of white blood cell responsible for producing antibodies to fight infections.12 The malignant cells grow rapidly in lymph nodes or other organs and can spread quickly throughout the body.11 These abnormal cells are larger than normal, healthy B-cells. Diffuse (D) LBCL is the most common and aggressive type where cells are spread out (diffuse) rather than grouped together when they are examined under a microscope.11 DLBCL accounts for approximately 40 percent of all NHL cases globally and is estimated to have 150,000 new cases diagnosed each year.13 While some patients respond to initial treatment, up to 40 percent can relapse or become refractory to therapy.14 LBCL and DLBCL patients often face limited treatment options and a poor prognosis, highlighting the urgent need for innovative therapies. Common symptoms include rapidly growing lymph nodes, fever, night sweats, weight loss, and fatigue.11

    About Warm Autoimmune Hemolytic Anemia
    Warm autoimmune hemolytic anemia (wAIHA) is a rare, life-threatening condition where autoantibodies lead to the premature destruction of red blood cells (RBCs), resulting in anemia.15 Approximately 1-3 new people per 100,000 are affected by wAIHA per year, and about 1 in 8,000 individuals are living with the condition.14,16 This condition affects both women and men and can affect people at any age with incidence increasing over the age of 50.15,17 Additionally, people with wAIHA are at increased risk of other serious complications such as venous thrombotic events, acute renal failure, and infection.18

    There are no Food and Drug Administration (FDA)-approved drugs indicated for wAIHA, and treatment typically consists of corticosteroids, broad immunosuppressants and B-cell directed therapies.14 With an unmet need for treatment in wAIHA, continued research for evidence-based potential therapies is critical.17

    About CARVYKTI®
    CARVYKTI® (cilta-cel) received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.19 In April 2024, CARVYKTI® was approved in the U.S. fortreatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor, an immunomodulatory agent, and who are refractory to lenalidomide, following a unanimous (11 to 0) FDA Oncologic Drugs Advisory Committee (ODAC) recommendation in support of this new indication. In April 2024, the European Medicines Agency (EMA) approved a Type II variation for CARVYKTI® for the treatment of adults with relapsed and refractory multiple myeloma who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. In September 2022, Japan’s Ministry of Health, Labour and Welfare (MHLW) approved CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma in patients that have no history of CAR-positive T cell infusion therapy targeting BCMA and who have received three or more lines of therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody, and in whom multiple myeloma has not responded to or has relapsed following the most recent therapy.

    CARVYKTI® is a BCMA-directed, autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR-positive T cells to eliminate cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. The CARVYKTI® CAR protein features two BCMA-targeting single domains designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells.

    In December 2017, Janssen Biotech, Inc., a Johnson & Johnson company, entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialize CARVYKTI®.

    For more information, visit www.CARVYKTI.com.

    About DARZALEX FASPRO® and DARZALEX®
    DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for ten indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible.1,4 It is the only subcutaneous CD38-directed antibody approved to treat patients with multiple myeloma. DARZALEX FASPRO® is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology.

    DARZALEX® (daratumumab) received U.S. FDA approval in November 2015 and is approved in ten indications, four of which are in the frontline setting, including newly diagnosed patients who are transplant eligible and ineligible.

    DARZALEX® is the first CD38-directed antibody approved to treat multiple myeloma. DARZALEX®-based regimens have been used in the treatment of more than 618,000 patients worldwide.

    In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen Biotech, Inc. an exclusive license to develop, manufacture and commercialize daratumumab.

    Since 2020, the National Comprehensive Cancer Network® (NCCN®) has recommended daratumumab-based combination regimens for the treatment of newly diagnosed multiple myeloma and relapsed and refractory multiple myeloma. For newly diagnosed multiple myeloma in non-transplant candidates, the NCCN® guidelines recommend daratumumab in combination with lenalidomide and dexamethasone as a Category 1 preferred regimen; daratumumab in combination with bortezomib, melphalan, and prednisone as another recommended Category 1 regimen; and daratumumab in combination with bortezomib, cyclophosphamide, and prednisone as another recommended Category 2A regimen. For newly diagnosed multiple myeloma in transplant candidates, the NCCN® guidelines recommend daratumumab in combination with bortezomib, lenalidomide and dexamethasone as another recommended Category 2A regimen; daratumumab in combination with bortezomib, thalidomide and dexamethasone as a Category 2A regimen useful in certain circumstances; daratumumab in combination with carfilzomib, lenalidomide and dexamethasone as a Category 2A regimen useful in certain circumstances; and daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone as a Category 2A regimen useful in certain circumstances. For maintenance in transplant candidates, the NCCN guidelines recommend daratumumab in combination with lenalidomide as useful in certain circumstances. In relapsed/refractory myeloma, four daratumumab regimens are listed as Category 1 preferred regimens for early relapses (1-3 prior therapies): daratumumab in combination with lenalidomide and dexamethasone; daratumumab in combination with bortezomib and dexamethasone; daratumumab in combination with carfilzomib and dexamethasone; and daratumumab in combination with pomalidomide and dexamethasone [after one prior therapy including lenalidomide and a proteasome inhibitor (PI)]. The NCCN® also recommends daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone as another Category 2A regimen for early relapses (1-3 prior therapies) and as monotherapy as a Category 2A regimen useful in certain circumstances for early relapse patients after at least three prior therapies, including a PI and an immunomodulatory agent, or for patients who are double refractory to a PI and an immunomodulatory agent.

    For more information, visit www.DARZALEX.com.

    About IMBRUVICA®
    IMBRUVICA® (ibrutinib) is a once-daily oral medication that is jointly developed and commercialized by Janssen Biotech, Inc., and Pharmacyclics LLC, an AbbVie company. IMBRUVICA® blocks the BTK protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread. By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments and inhibit their proliferation.20,21,22

    IMBRUVICA® is approved in more than 100 countries and has been used to treat more than 325,000 patients worldwide over the last decade. There are more than 50 company-sponsored clinical trials, including 18 Phase 3 studies, spanning more than 11 years, evaluating the efficacy and safety of IMBRUVICA®.

    IMBRUVICA® was first approved by the U.S. FDA in November 2013, and today is indicated for adult patients in four disease areas. These include indications to treat adults with chronic lymphocytic leukemia/small lymphocytic lymphoma with or without 17p deletion; adults with Waldenström’s macroglobulinemia; and adult and pediatric patients aged one year and older with previously treated chronic graft versus host disease after failure of one or more lines of systemic therapy.23

    About TALVEY®
    TALVEY® (talquetamab-tgvs) received approval from the U.S. FDA in August 2023 as a first-in-class GPRC5D-targeting bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.24 Since FDA approval, 7,700 patients were treated with TALVEY®. The European Commission (EC) granted conditional marketing authorization (CMA) of TALVEY® (talquetamab-tgvs) in August 2023 as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.25

    TALVEY® is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D), a novel multiple myeloma target which is highly expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as some healthy tissues such as epithelial cells of the skin and tongue.  

    About TECVAYLI®
    TECVAYLI® (teclistamab-cqyv) received approval from the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.26 Since FDA approval, more than 20,800 patients have been treated worldwide with TECVAYLI®. The European Commission (EC) granted TECVAYLI® conditional marketing authorization (CMA) in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023, the EC granted the approval of a Type II variation application for TECVAYLI®, providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In February 2024, the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI® for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months.

    For more information, visit www.TECVAYLI.com.

    About Johnson & Johnson
    At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Janssen Research & Development, LLC, Janssen Biotech, Inc., Janssen Global Services, LLC and Janssen Scientific Affairs, LLC are Johnson & Johnson companies.

    Cautions Concerning Forward-Looking Statements
    This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of CARVYKTI® (ciltacabtagene autoleucel), DARZALEX® (daratumumab), DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), IMBRUVICA® (ibrutinib), TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    Footnotes
    1 Rajkumar SV. Multiple Myeloma: 2020 update on diagnosis, risk-stratification and management. American Journal of Hematology, 95(5), 548–567. https://doi.org/10.1002/ajh.25791

    2 National Cancer Institute. (2025, October). Plasma cell neoplasms. National Institutes of Health. Retrieved October 2025, from https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq

    3 City of Hope. (2022). Multiple myeloma: Causes, symptoms & treatments. Retrieved October 2025, from https://www.cancercenter.com/cancer-types/multiple-myeloma

    4 American Cancer Society. (2025, October). Myeloma cancer statistics. Retrieved from https://cancerstatisticscenter.cancer.org/types/myeloma

    5 Surveillance Research Program, National Cancer Institute. (2025, May). SEER Explorer: An interactive website for SEER cancer statistics [Internet]. National Institutes of Health. Retrieved from https://seer.cancer.gov/explorer/

    6 American Cancer Society. (2025, October). What is multiple myeloma? Retrieved from https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html

    7 American Cancer Society. (2025, October). Multiple myeloma early detection, diagnosis, and staging. Retrieved from https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html

    8 The Leukemia & Lymphoma Society. (2023). Facts 2022–2023: Updated data on blood cancers. Retrieved October 2025, from https://www.lls.org/sites/default/files/2023-08/PS80_Facts_2022_2023.pdf

    9 MD Anderson Cancer Center. (2025, October). Acute myeloid leukemia. Retrieved from https://www.mdanderson.org/cancer-types/acute-myeloid-leukemia.html

    10 American Cancer Society. (2025, October). Signs and symptoms of acute myeloid leukemia (AML). Retrieved from https://www.cancer.org/cancer/types/acute-myeloid-leukemia/detection-diagnosis-staging/signs-symptoms.html

    11 Shimony, S., Stahl, M., & Stone, R. M. (2023). Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 98(3), 502–526. https://doi.org/10.1002/ajh.26822

    12 Lymphoma Action. (2025, October). Diffuse large B-cell lymphoma. Retrieved from https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/diffuse-large-b-cell-lymphoma

    13 Berhan, A., et al. (2025, February 15). Diffuse large B cell lymphoma (DLBCL): Epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: Narrative review. Discover Oncology, 16, 184. https://link.springer.com/content/pdf/10.1007/s12672-025-01958-w.pdf

    14 García-Sancho, A. M., et al. (2023, December 22). Treatment of relapsed or refractory diffuse large B-cell lymphoma: New approved options. Journal of Clinical Medicine, 13(1), 70. https://www.mdpi.com/2077-0383/13/1/70.

    14 National Organization for Rare Disorders. (2025, October). Warm autoimmune hemolytic anemia. Retrieved from https://rarediseases.org/rare-diseases/warm-autoimmune-hemolytic-anemia/

    16 Tranekær, S., Hansen, D. L., & Frederiksen, H. (2021, March 17). Epidemiology of secondary warm autoimmune haemolytic anaemia: A systematic review and meta-analysis. Journal of Clinical Medicine, 10(6), 1244. https://doi.org/10.3390/jcm10061244

    17 Cherif, H., Cai, Q., Crivera, C., Leon, A., Rahman, I., Leval, A., Noel, W., & Kjellander, C. (2024). Overall survival and treatment patterns among patients with warm autoimmune hemolytic anemia in Sweden: A nationwide population-based study. European Journal of Haematology. https://doi.org/10.1111/ejh.14311

    18 Fattizzo, B., & Barcellini, W. (2022, October). New therapies for the treatment of warm autoimmune hemolytic anemia. Transfusion Medicine Reviews, 36(4). https://doi.org/10.1016/j.tmrv.2022.08.001

    19 CARVYKTI® U.S. Prescribing Information.

    20 National Library of Medicine. (2025, October). Isolated growth hormone deficiency. Retrieved from http://ghr.nlm.nih.gov/condition/isolated-growth-hormone-deficiency

    21 Turetsky, A., et al. (2014). Single cell imaging of Bruton’s tyrosine kinase using an irreversible inhibitor. Scientific Reports, 6, 4782.

    22 de Rooij, M. F., Kuil, A., Geest, C. R., et al. (2012). The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood, 119(11), 2590–2594.

    23 IMBRUVICA® U.S. Prescribing Information, August 2022.

    24 TALVEY® U.S. Prescribing Information, August 2023.

    25 European Medicines Agency. TALVEY Summary of Product Characteristics. August 2023.

    26 Johnson & Johnson. (2025, October). U.S. FDA approves TECVAYLI® (teclistamab-cqyv), the first bispecific T-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma. Retrieved from https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma


    Continue Reading

  • Trump turns crypto pariahs into power players – Politico

    1. Trump turns crypto pariahs into power players  Politico
    2. Trump says US must stay number one as China ramps up crypto push  Geo TV
    3. Trump Just Issued A ‘Very Big’ China Warning As Bitcoin Teeters On The Verge Of A Major $100,000 Price Crash  Forbes
    4. President Trump talks crypto, corruption and Changpeng Zhao in ’60 Minutes’ interview  theblock.co
    5. Peter Schiff Blasts Trump’s China Narrative On Crypto: Beijing Has No Interest In Leading The World In ‘Ponzi Schemes’  Benzinga

    Continue Reading

  • Journal of Medical Internet Research

    Journal of Medical Internet Research

    YouTube as a Participatory Platform for Health-Compromising Discourse

    Digital platforms are now central to public discourse. YouTube strongly influences opinion and social norms through its algorithmic system and creator-driven content [-]. Across domains—news, health, education, and politics—it serves as a primary information gateway, bypassing traditional media filters and enabling decentralized participation []. Yet, this openness also enables harmful discourse, including misinformation, health-compromising content, and hate speech, threatening public health and social cohesion.

    A clear example is “pro-anorexia” (pro-ana) discourse, which glamorizes extreme dieting. These narratives reframe anorexia’s pathological traits as esthetic and moral ideals, creating communities around “thinspiration” images, restrictive meal plans, exercise regimens, and weight-loss stories [-]. They strongly affect adolescent females, provoking identity responses. Within these groups, starvation and bodily discipline appear as self-development and social validation tools [-]. Although members may gain emotional support and collective identity [,-], they remain vulnerable to anxiety, shame, and self-hatred when failing to meet body norms [,].

    Algorithmic Structuring and Fragmentation of Pro-Ana Communities

    YouTube recontextualizes pro-ana discourse differently from image-centric platforms like Instagram and Pinterest. Its mixed-genre videos—vlogs, challenges, and reviews—embed “body talk” into everyday narratives [,]. In this space, where production and consumption overlap, users develop bonds with creators via comments, likes, and subscriptions. This accelerates discourse cohesion, evolving into “video-based communities” built on shared beliefs []. These groups are defined by recurrently consumed, interacted-with videos, forming cognitive and emotional structures beyond playlists or channels—platform-based collectives driven by affect and action.

    YouTube’s algorithm strengthens such collectives by analyzing behavioral data—clicks, watch time, comments, and subscriptions—to repeatedly recommend similar content [,]. This fosters “filter bubbles” and “echo chambers,” reinforcing preferences while limiting alternative exposure [,]. Content with high engagement circulates more widely, amplifying intervideo connectivity through shared audiences [,]. Prior research highlights interactivity, repetition, emotional resonance, and network structures as central to shaping these communities [,-].

    While YouTube’s algorithmic curation and creator-viewer interactivity foster cohesion among similarly framed content, they hinder bridging across divergent frames [,]. Pro-ana advocacy videos often employ emotionally charged personal storytelling, eliciting empathetic engagement that is algorithmically amplified [,], which creates closed clusters []. In contrast, anti–pro-ana and recovery content, largely from public health perspectives, remains informational and authoritative, making it less effectively engaging and rarely connected to pro-ana communities [,,,]. Thus, pro-ana content forms dense but isolated clusters.

    Within YouTube’s fragmented discursive ecology, pro-ana discourse functions not as a unified sphere but as heterogeneous clusters organized around competing frames. Fragmentation aligns with channel type. Institutional channels, run by news outlets or agencies, deliver authoritative critiques of disordered behaviors using credibility and infrastructure [-]. Conversely, many individual creators—neither health professionals nor public figures [,]—share autobiographical narratives that glorify thinness or describe recovery, fostering emotional immersion and parasocial bonds, and sometimes integrate monetization strategies [,,,].

    Strategic Role of Recovery Frames and Meso-Level Channels

    Subscriber scale influences video visibility, framing styles, and engagement. “Meso-level” creator channels—moderate in subscribers—often balance reach and intimacy. They outperform large-scale channels in emotional resonance and exceed micro-channels in visibility, making them potential “bridges” for disrupting clusters and introducing alternative frames [,]. Exploring how these channels foster frame intersection is crucial for mitigating pro-ana health risks.

    Few studies have assessed the structural organization of pro-ana discourse on YouTube or strategies for transforming it into intersectable networks. Prior work has emphasized social support and emotional bonds from pro-ana messaging, showing advocacy’s appeal over prevention [,] while noting the marginalization of recovery narratives []. Yet, most analyses have focused on individual video content, neglecting intervideo ties and frame diffusion from a network perspective [,].

    Accordingly, this study analyzed network-level relationships among pro-ana advocacy, anti–pro-ana, and recovery frames on YouTube. It investigated whether pro-ana discourse is structurally enclosed within platform clusters and explored strategies for more effective public health messaging. Specifically, we assessed whether recovery or anti–pro-ana narratives generate wider engagement and how they operate within the broader video network.

    We emphasized the strategic value of the “recovery frame,” often conveyed through autobiographical confessions by former pro-ana individuals. Such narratives reframe eating disorders as emotionally resonant journeys, blending information and affective appeal [,]. With this hybrid structure, recovery frames can align with algorithmic preference while retaining emotional pull [,]. We tested whether recovery narratives, delivered through suitable channels, soften boundaries and enable cross-frame interaction.

    This study situated the analysis in Korea, where idol-driven thinness ideals and self-discipline ethics strongly shape young women’s body norms []. It diagnosed structural isolation among pro-ana frames and evaluated recovery’s potential for diffusion. This will expand theories of platform-based health risk communication and guide youth protection strategies, including algorithm adjustment, targeted monitoring, and channel-specific messaging. Ultimately, the study will advance communication models that address emotionally driven, closed discourse communities.

    Research Questions

    In the digital era, health discourse is no longer expert-led and unidirectional. On participatory platforms like YouTube, algorithmic curation and user activity drive sophisticated, fragmented modes of dissemination and transformation. Within this environment, pro-ana discourse—glamorizing pathological body images—emerges as a public health threat. Understanding how it spreads and evolves structurally is urgent. This study examined how pro-ana discourse is produced and consumed through framing strategies and how these frames form distinct network structures shaped by algorithms and engagement.

    As the first research question (RQ1), this study analyzed framing differences by channel operator (institutional vs individual) and subscriber scale (mega, meso, or micro). Unlike prior studies that focused on video content or anecdotal cases [,,,], this study empirically assessed how channel structure and scale influence frame selection and organization. This approach highlights discourse diversity and differentiation while offering insights for targeted public health interventions.

    The second research question (RQ2) explored how pro-ana–related videos form structural networks through viewer engagement and how these networks evolve. It examined how channel attributes and framing strategies align within viewer-driven video networks. A video-level network was built using commenter overlap to define intervideo ties. Structural indicators—density, modularity, and community count—were analyzed longitudinally. This study tested the claim that pro-ana discourse comprises multiple “refracted publics” rather than a unified sphere []. It also assessed whether algorithms and user activity create increasingly enclosed, fragmented structures. As homogeneity strengthens, networks are expected to cluster tightly, with dense internal ties and sparse external links—hallmarks of echo chambers [].

    The third research question (RQ3) examined how channel characteristics and frame attributes influence intervideo connections using the exponential random graph model (ERGM). Beyond descriptive engagement, the ERGM evaluates when frame-based homophily strengthens and when heterogeneous ties capable of bridging emerge. Special focus was given to meso-level individual channels, which—with moderate subscriber bases—may act as bridges when paired with anti–pro-ana or recovery frames. By identifying these roles, this study aimed to develop strategies for frame-channel collaboration in public health communication to counter the structural fragmentation and closure of pro-ana discourse on YouTube.

    Ethical Considerations

    This study analyzed only publicly available YouTube videos and comments; no private content was included. Public user handles were used only when necessary; however, all handles were deidentified in any shared datasets and were not publicly released. Data collection complied with the YouTube Data API Terms of Service and relevant legal guidelines. Researchers had no direct interaction with users. Since the study used noninterventional, publicly accessible, nonidentifiable data with minimal risk, no formal ethics review was required.

    Data Collection

    To analyze Korean-language YouTube discourse on eating disorders and extreme dieting, we used a multistage strategy in August 2024 via the YouTube Data API (v3). The procedure included (1) exploratory seed video retrieval, (2) expansion through algorithmically recommended videos, and (3) topic-based filtering and refinement.

    Stage 1: Seed Video Retrieval

    We identified seed videos using 4 Korean search terms linked to pro-ana and extreme dieting: “프로아나” (pro-ana), “프아 다이어트” (pro-ana diet), “뼈말라” (ppyeo-malla; “bone-thin”), and “개말라” (gae-malla; “extremely skinny”). These keywords were drawn from prior studies [,] and discourse analyses in Korean online communities. Using the YouTube Data API’s search.list endpoint, we retrieved top-ranked videos for each keyword by relevance. Videos explicitly tagged or described as pro-ana or extreme dieting formed the initial seed sample.

    Stage 2: Expansion via Related Videos

    To capture YouTube’s algorithmic exposure, we collected “related videos” for each seed video from the sidebar and autoplay suggestions. Because recommendations depend on viewing history, we used a clean, no-history account—free of logins, subscriptions, or prior views—to scrape related data. This reduced personalization bias and more objectively reflected default exposure chains [].

    Stage 3: Sample Refinement

    The initial corpus included 4174 videos. We refined the sample by (1) restricting publication to the period from January 2020 to August 2024, aligning with pandemic-linked increases in youth disordered eating []; (2) removing duplicates and videos without comment sections; and (3) excluding off-topic content after reviewing titles, descriptions, and transcripts. Videos without pro-ana advocacy, anti–pro-ana critique, or recovery promotion were discarded. The final dataset comprised 489 videos from 160 channels. Metadata included video ID, view count, comment count, channel name, and subscriber count ().

    YouTube Channel Classification

    To evaluate how channel traits influence frame choice and network structure, we classified channels along 2 dimensions: operational entity (individual vs institutional) and subscriber size (mega, meso, or micro). This scheme reflects institutional embeddedness and communicative reach, providing meaningful strata for analyzing framing strategies and network positions.

    Operational Entity

    Channels were coded as institutional or individual. Institutional channels included those managed by news outlets, broadcasters, health organizations, hospitals, public agencies, celebrity agencies, or corporations. These typically display organizational names and standardized formats. Individual channels, operated by single creators, often feature vlogs, diet routines, or testimonials, and may share personal contact details for sponsorship. This distinction captures ownership, production intent, trustworthiness, audience expectations, and algorithmic visibility [].

    Subscriber Size

    Subscriber count, a proxy for social influence and algorithmic visibility, was divided into 3 tiers based on influencer marketing literature [,]: mega (≥1,000,000 subscribers), meso (100,000-999,999 subscribers), and micro (10,000-99,999 subscribers).

    Combining the 2 dimensions produced 6 channel types: mega-institution, mega-individual, meso-institution, meso-individual, micro-institution, and micro-individual. Meso-individual channels held the largest share (302/489, 61.8%), followed by micro-individual channels (129/489, 26.4%), showing that small- to mid-sized individual creators drive pro-ana discourse on Korean YouTube ().

    Table 1. Channel and video characteristics by channel category in YouTube pro-anorexia discourse (2020‐2024).
    Category Channels (N=160), n (%) Average subscribers, n Videos (N=489), n (%) Average views, n
    Mega-institution 21 (13.1) 2,676,190 26 (5.3) 1,216,276
    Mega-individual 3 (1.9) 2,220,000 4 (0.8) 2,980,878
    Meso-institution 19 (11.9) 487,211 20 (4.1) 645,684
    Meso-individual 35 (21.9) 335,057 302 (61.8) 706,627
    Micro-institution 7 (4.4) 43,864 8 (1.6) 214,262
    Micro-individual 75 (46.9) 14,472 129 (26.4) 246,226

    Mega-individual channels, though fewer, recorded the highest average views per video, indicating disproportionately broad reach (). In contrast, meso- and micro-individual channels were central to grassroots production and engagement, making them structurally pivotal for network propagation. These classifications were later used as independent variables to explain frame distribution (RQ1), community structure (RQ2), and edge formation (RQ3).

    Frame Analysis for RQ1

    To address RQ1, we analyzed 489 YouTube videos to examine tensions between pro-ana narratives and public health counter-responses. Frames are defined here as interpretive structures that shape audiences’ problem recognition, emotions, and attitudes by guiding how issues are presented [,]. While traditional media once centralized frame dissemination, digital media now enables YouTubers to influence audiences through algorithmically optimized strategies [,]. Creators often use sensational or boundary-setting discourse to define “normal” bodies and acceptable behavior []. In health-risk discourses like pro-ana, frames serve not just as information vehicles but also as mechanisms for belief formation and identity performance [,]. When algorithmically reinforced, frame fragmentation intensifies polarization [,].

    Based on prior studies, we categorized 3 major frames in pro-ana YouTube content. The pro-ana advocacy frame glamorizes extreme weight loss and presents thinness as ideal beauty, portraying practices as self-discipline or growth. Examples include diet vlogs, body-check challenges, and calorie tutorials, often embedded in the narratives of effort and transformation []. Creators position themselves as role models through microcelebrity strategies, embodying beauty and willpower. Their emotional bonds with followers reproduce the pro-ana frame [,].

    In contrast, the anti–pro-ana frame stresses the dangers of extreme dieting and the harms of pro-ana narratives. It appears mainly in institutional channels, such as news media or expert-led accounts, using formats like news clips, interviews, and warning narratives. These videos critique sociocultural pressures that valorize thinness, reject normalization of pro-ana discourse, and emphasize the ethical need for intervention [,].

    Lastly, the recovery frame centers on personal recovery from eating disorders, such as food diaries and mental health stories. These autobiographical accounts evoke empathy and identification among viewers, introducing decentered voices that disrupt pro-ana communities [,]. Expressive strategies include autobiographical narration, contrastive references to past videos, and audience feedback loops.

    The frame typology was operationalized through a coding scheme as presented in , which outlines subframes under each primary frame. Subframes were coded using a multi-label strategy and aggregated under the primary frame. When multiple frames appeared in a video, dominance was determined by subframe frequency, with coder agreement resolving inconsistencies.

    Table 2. Operational definitions and examples of pro-ana video frames.
    Main frame and subframe Definition Example Prior studies
    Pro-ana advocacy
    Thinness glorification Frames extreme thinness as beauty and an aspirational value. Idolizing emaciated celebrity bodies and sharing strict diet before-after images. [,]
    Self-control Presents diet and exercise as essential practices for achieving an ideal body. Framing fasting or intense workouts as a healthy discipline. [,]
    Self-harm Links thinness pursuit to fear, guilt, and harmful behaviors. Linking weight-loss failure to anxiety and shame. [,]
    Anti–pro-ana
    Disruption of everyday life Positions anorexia as a disorder threatening health and daily life. Depicts isolation, family strain, or health crises caused by disordered eating. []
    Personal responsibility Attributes pro-ana practices to the personal pursuit of thinness. Criticizes young people who imitate celebrity thinness for self-gratification. []
    Societal responsibility Blames cultural and media pressures (eg, idol culture and social media) for promoting pro-ana norms. Argues that idol-driven beauty norms fuel eating disorders among young women. []
    Recovery
    Restoration of everyday life Highlights return to normal eating and daily routines after recovery. Sharing meal plans or journals documenting healthy weight recovery. [,]
    Self-reflection Promotes body acceptance, regret over harmful behaviors, and hope for future well-being. Recalling past self-harm while expressing renewed motives for self-care. [,]

    apro-ana: pro-anorexia.

    The coding team included 2 master’s students in media studies. After a pilot phase refining definitions and examples, independent coding was applied to all 489 videos. Intercoder reliability was assessed by double-coding 154 random videos (31% of the total), yielding Cohen κ values of 0.78-0.83 across frames, which indicate substantial agreement and coding validity.

    Social Network Analysis for RQ2

    To address RQ2, we used social network analysis (SNA) to examine how pro-ana videos are linked through shared commenters and how these links reflect temporal shifts in discursive cohesion and fragmentation. A video-level network was built from commenter overlap. Using the commentThreads endpoint of the YouTube Data API, we collected comments and user IDs from the 489 videos. The dataset included 1,21,991 comments (range 1‐4935; mean 254.5, SD 411.2), providing a large sample for interaction analysis ().

    Stage 1: Network Construction

    We built a 2-mode (video×user) affiliation matrix linking each video to its top commenters and then projected it onto a 1-mode (video×video) network. An edge between videos A and B was created if at least one user commented on both []. To reduce distortions from popular videos or high-subscriber channels [], edge weights were defined as the proportion of commenters on video A who also commented on video B, normalizing for exposure scale [].

    Stage 2: Backbone Extraction

    To retain only statistically meaningful ties in the skewed comment network, we applied the disparity filter, which preserves edges exceeding random expectation thresholds (P<.05) []. This extracted the network’s significant backbone, isolating structural ties indicative of discourse cohesion.

    Stage 3: Community Detection and Structural Indicators

    On the backbone network, we calculated global metrics, such as density, community count, and modularity, to assess cohesion. The Louvain algorithm was used for community detection []. Modularity values show how well the network is divided into modules with dense internal and sparse external ties []; higher values indicate echo chamber–like clusters resistant to frame crossover.

    Stage 4: Time-Series Network Dynamics

    To capture structural change over time, we split the dataset into quarterly periods and repeated backbone extraction, metric calculation, and community detection for each. This longitudinal approach tracked network shifts before and after the COVID-19 pandemic.

    ERGM Analysis

    To address RQ3, we used the ERGM to identify factors explaining why pro-ana YouTube videos are connected via shared commenters. Unlike descriptive SNA, which characterizes observed structures, the ERGM models the likelihood of edge formation from node attributes and structural dependencies []. This method is effective for revealing structural conditions driving public health risks, focusing not on individual content but on how information is linked, isolated, or diffused [].

    The dependent variable was a binary indicator: 1 when two videos shared at least one commenter, and 0 otherwise, based on the backbone-pruned video network. This captured the presence of a narrative contagion path from a user-driven perspective.

    Explanatory variables included channel type and dominant frame. Channel types were grouped into 6 categories based on ownership (institutional vs individual) and subscriber scale (mega, meso, or micro). Frames were coded as pro-ana, anti–pro-ana, or recovery. All variables were categorical.

    To capture echo chamber dynamics, we added a nodematch term for frame homogeneity (whether connected videos shared the same frame). We also modeled interaction terms between channel type and frame to test whether specific combinations were more likely to produce user overlap and cross-frame ties.

    Controls included (1) absolute difference in video views (log-transformed), (2) same-channel indicator (dummy variable), and (3) upload date gap in days. These accounted for exposure scale, channel ownership effects, and temporal proximity. Auxiliary models also included the GWESP (Geometrically Weighted Edgewise Shared Partners) term to capture transitivity, ensuring robustness of main effects.

    The model was estimated using the ergm package in R via Markov chain Monte Carlo maximum likelihood estimation []. Convergence was checked with trace plots and autocorrelation functions, adjusting tuning parameters, such as burn-in, thinning, and step size, to stabilize standard errors. Coefficients were reported in log-odds and converted into odds ratios for interpretability.

    Model fit was assessed through simulation-based goodness-of-fit tests comparing observed and simulated statistics (degree distribution, geodesic distances, and shared partners). Robustness was tested by (1) varying the backbone filter’s α level (α=.01, .05, or .10), (2) replicating the model on a binarized unfiltered weighted network, and (3) applying identical model specifications across quarterly networks to compare pre- and postpandemic structural change.

    Our analytical framework () moves beyond video-level content evaluation by statistically identifying combinations of content and structural conditions that facilitate discourse diffusion. It also highlights strategic public health messaging targets within emotionally driven, algorithmically reinforced discourse environments.

    Figure 1. Research flow. API: application programming interface; MCMC: Markov chain Monte Carlo; pro-ana: pro-anorexia.

    Use of Frames by Channel Type

    We cross-tabulated 8 subframes of pro-ana discourse across 6 channel types () and analyzed their distributions. Because videos may include multiple subframes—potentially violating independence assumptions of the chi-square test—and some cells had low counts, we used Monte Carlo–approximated Fisher exact tests by frame. As a sensitivity check, a Monte Carlo chi-square test was also applied to the full table, confirming a highly significant association between subframes and channel type (Monte Carlo χ235=585.12; P<.001).

    Table 3. Distribution of pro-ana subframes in 489 YouTube videos by channel type (2020-2024).
    Main frame and subframe Mega-level Meso-level Micro-level
    Institution (N=26), n (%) Individual (N=4), n (%) Institution (N=20), n (%) Individual (N=302), n (%) Institution (N=8), n (%) Individual (N=129), n (%)
    Pro-ana advocacy
     Thinness glorification 2 (7.7) 1 (25.0) 2 (10.0) 61 (20.2) 0 (0.0) 51 (39.5)
     Self-control 2 (7.7) 3 (75.0) 2 (10.0) 276 (91.5) 0 (0.0) 44 (34.1)
     Self-harm 1 (3.9) 0 (0.0) 0 (0.0) 6 (2.0) 0 (0.0) 5 (4.0)
    Anti–pro-ana
     Disruption of everyday life 20 (76.9) 0 (0.0) 16 (80.0) 8 (2.7) 6 (75.0) 10 (7.8)
     Personal responsibility 7 (26.9) 1 (25.0) 6 (30.0) 0 (0.0) 6 (75.0) 7 (5.4)
     Societal responsibility 13 (50.0) 0 (0.0) 9 (45.0) 1 (0.3) 4 (50.0) 3 (2.3)
    Recovery
     Restoration of everyday life 2 (7.7) 0 (0.0) 1 (5.0) 2 (0.7) 0 (0.0) 44 (34.1)
     Self-reflection 2 (7.7) 0 (0.0) 1 (5.0) 2 (0.7) 0 (0.0) 12 (9.3)

    apro-ana: pro-anorexia.

    bAs multiple subframes could be assigned to a video, totals for each channel type may exceed the number of videos in that category.

    Pro-ana advocacy subframes (thinness glorification, self-control, and self-harm) were concentrated in individual channels, especially meso- and micro-individual channels. Standardized residuals showed that self-control was far more frequent in meso-individual channels (z=14.95), while thinness glorification was more frequent in micro-individual channels (z=4.30). These results suggest that mid- and small-scale channels incubate messages glorifying thinness and reframing disordered eating as “self-discipline.”

    Anti–pro-ana subframes (disruption of everyday life, personal responsibility, and societal responsibility) were concentrated in institutional channels. Mega- and meso-institutional channels exceeded expectations for disruption of everyday life (z=7.85 and 7.27, respectively), and both personal responsibility and societal responsibility were overrepresented in mega-institutional channels (z=3.64 and 7.52, respectively) and meso-institutional channels (z=3.74 and 5.82, respectively). These findings confirm that legacy media and professional channels drive critical discourse on eating disorder risks and societal responsibilities.

    Recovery subframes, especially restoration of everyday life and self-reflection, appeared mainly in micro-individual channels. Restoration of everyday life was significantly above expectation (z=10.15; P<.001), with self-reflection also elevated (z=4.03; P<.001). This suggests that intimate, recovery-oriented narratives are most clearly articulated by a small-scale creator.

    When subframes were aggregated into 3 primary frame categories and reanalyzed (), channel type and frame category again showed a significant association (χ210=397.10; P<.001). Post hoc residuals indicated strong overrepresentation of pro-ana advocacy in meso-individual channels (z=13.86); anti–pro-ana in mega- (z=10.71) and meso-institutional channels (z=8.72); and recovery in micro-individual channels (z=11.08).

    Table 4. Frequency of videos (N=489) featuring pro-ana frames by YouTube channel type.
    Variable Mega-level Meso-level Micro-level
    Institution (N=26), n (%) Individual (N=4), n (%) Institution (N=20), n (%) Individual (N=302), n (%) Institution (N=8), n (%) Individual (N=129), n (%)
    Pro-ana advocacy 2 (7.7) 3 (75.0) 3 (15.0) 292 (96.7) 0 (0.0) 69 (53.5)
    Anti–pro-ana 22 (84.6) 1 (25.0) 16 (80.0) 8 (2.6) 8 (100.0) 13 (10.1)
    Recovery 2 (7.7) 0 (0.0) 1 (5.0) 2 (0.7) 0 (0.0) 47 (36.4)

    apro-ana: pro-anorexia.

    These results reveal a bifurcated ecosystem: mid-scale individuals diffuse pro-ana advocacy, large institutional channels anchor anti–pro-ana critique, and small individual creators host recovery narratives. Recovery’s concentration in micro-individual channels suggests limited diffusion, underscoring the need for bridging strategies to broaden reach.

    Community Structure of the Pro-Ana Video Network

    After backbone filtering, we built a commenter-overlap network with 435 videos and 906 edges representing shared audiences (). Node degrees ranged from 1 to 247, with a median of 1, showing that most videos shared audiences with only a few others. Network density was low (0.96%). Louvain community detection identified 19 modules, with modularity at 0.58, suggesting closed subgroups with strong internal ties but sparse external links. Thus, pro-ana discourse resembles a fragmented ecology of isolated modules rather than a unified sphere.

    To extend this static snapshot, quarterly networks were analyzed () for density, modularity, and community count. Density was higher in late 2020 but fell sharply after mid-2021 (Kwiatkowski-Phillips-Schmidt-Shin [KPSS] P=.049), showing weakened audience overlap. Modularity increased across the period (KPSS P=.046), indicating echo chamber intensification as similar-frame videos increasingly shared commenters. Community counts peaked in Q4 2022 but fluctuated without a clear trend (KPSS P=.07). Overall, the postpandemic network grew more polarized into homogeneous, self-reinforcing clusters.

    Table 5. Backbone commenter-overlap network derived from 489 pro-ana YouTube videos.
    Term Definition Value in the observed network
    Node Fundamental network unit; here, each node represents a single pro-ana YouTube video. 435
    Edge Connection between 2 nodes, indicating meaningful commenter overlap—ie, at least a minimum number of shared commenters. 906
    Degree Number of edges incident on a node, showing how many videos are directly linked through shared commenter activity. Range: 1-247; median=1
    Density Proportion of observed to possible edges, measuring overall connectivity. 0.96%
    Modularity (number of communities) Degree to which the network decomposes into dense internal ties and sparse external ties; includes the number of detected communities. 0.58 (19)

    apro-ana: pro-anorexia.

    Figure 2. Quarterly trends in structural properties of the pro-anorexia (pro-ana) YouTube commenter network (2020‐2024). This figure illustrates quarterly trends in density (A), modularity (B), and community (C) count for the pro-ana YouTube commenter-overlap network from Q4 2020 to Q3 2024. The network is constructed by linking videos based on shared commenters, with backbone extraction applied to retain only statistically significant connections. Network density reflects the concentration of comments, modularity measures the strength of clustering, and the number of communities indicates the degree of network fragmentation. Quarters with no surviving edges after backbone extraction are excluded.

    To analyze thematic content, we examined frame composition in the largest communities (). Community 1 (n=242) was almost entirely pro-ana, forming a dense core repeatedly drawing active commenters. Community 2 (n=79) mixed pro-ana, anti–pro-ana, and recovery frames, creating a more heterogeneous discursive space. By contrast, community 3 (n=13) was nearly all anti–pro-ana, and community 4 (n=25) was entirely recovery—both located at the periphery. These results suggest that critical and recovery messages occasionally penetrate the advocacy core but remain marginal, largely confined to peripheral enclaves. Overall, the pro-ana ecosystem is multitiered, dominated by an advocacy-centered core, with critical or recovery frames limited to sporadic bridging.

    Figure 3. Frame-based community structure of the pro-anorexia (pro-ana) video network on YouTube (2020‐2024). This network visualization illustrates the community structure of the pro-ana video network, based on commenter overlap among 489 YouTube videos from 2020 to 2024. Each node represents a video, and edges connect videos that share common commenters. Colors indicate the dominant frame type of each video: red for pro-ana advocacy, blue for anti–pro-ana, and green for recovery. The visualization highlights frame-based clustering and potential echo chambers within the pro-ana discourse on YouTube.

    ERGM Estimates

    For RQ3, we estimated 2 ERGMs with commenter-overlap edges as the dependent variable (). Model 1 included main effects for channel type, video frame, and frame-based homophily, and controls for log-transformed view count difference and same-channel membership. Model 2 added interaction terms between channel type and frame. Both models converged successfully and fit significantly better than a baseline edges-only model (model 1 Δdeviance=1109.04; P<.001).

    Table 6. Exponential random graph models predicting edge formation in the anorexia-related YouTube video network by channel and frame type.
    Variable Model 1 Model 2
    Edges −4.88 (0.26) −5.41 (0.33)
    Individual terms
    Channel type (reference: micro-personal)
      Mega-institution 1.41 (0.12) 1.80 (0.22)
      Mega-individual 1.78 (0.18) 2.11 (0.21)
      Meso-institution 1.12 (0.12) 1.31 (0.23)
      Meso-individual −0.75 (0.09) −1.10 (0.13)
      Micro-institution 1.32 (0.17) 1.82 (0.53)
    Video frame (reference: pro-ana advocacy)
      Anti–pro-ana −0.12 (0.23) 0.40 (0.29)
      Recovery 0.29 (0.18) 0.37 (0.29)
    Dyadic terms
    Homophily
      Anti–pro-ana 0.79 (0.24) 0.92 (0.33)
      Recovery frame 0.55 (0.28) 0.56 (0.40)
      Pro-ana advocacy 0.40 (0.23) 1.14 (0.31)
    Controls
      View count (absdiff) −0.77 (0.07) −0.78 (0.07)
      Channel ID (nodematch) 1.72 (0.13) 2.19 (0.16)
    Interaction terms
     Mega-institution×anti–pro-ana frame −0.40 (0.16)
     Mega-individual×anti–pro-ana frame −0.64 (0.26)
     Meso-institution×anti–pro-ana frame −0.24 (0.17)
     Meso-individual×anti–pro-ana frame 0.44 (0.15)
     Micro-institution×anti–pro-ana frame −0.44 (0.33)
     Mega-institution×recovery frame −0.03 (0.22)
     Mega-individual×recovery frame −0.65 (0.76)
     Meso-institution×recovery frame −0.22 (0.29)
     Meso-individual×recovery frame 0.95 (0.23)
     Micro-institution×recovery frame −0.06 (0.49)
    Model AIC 9566 9545
    Reduction in residual deviance (df)
    Compared with the edge-only model 1109.04 (12)
    Compared with model 1 40.99 (10)

    aResults are from 2 exponential random graph models testing factors influencing commenter-overlap edges among anorexia-related YouTube videos.

    bP<.001.

    cpro-ana: pro-anorexia.

    dP<.01.

    eNot applicable.

    fP<.05.

    gAIC: Akaike information criterion.

    In model 1, relative to micro-individual channels, videos from mega-institutional (β=1.41; P<.001; odds ratio [OR]=4.1), mega-individual (β=1.78; P<.001; OR=5.9), meso-institutional (β=1.12; P<.001; OR=3.1), and micro-institutional channels (β=1.32; P<.001; OR=3.8) showed a significantly higher likelihood of commenter sharing. By contrast, meso-individual channels had a significant negative effect (β=−0.75; P<.001; OR=0.47). While frame main effects were nonsignificant, strong homophily emerged for anti–pro-ana (β=0.79; P<.001; OR=2.20), meaning same-frame videos were more likely to share commenters. Pro-ana and recovery homophily were positive but nonsignificant. Among controls, larger view-count gaps reduced edge probability (β=−0.77; P<.001; OR=0.46), while same-channel videos were much more connected (β=1.72; P<.001; OR=5.58).

    Model 2, with interaction terms, improved fit (Δdeviance=40.99; P<.001). Pro-ana homophily became significant (β=1.14; P<.001; OR=3.12). The meso-individual×anti–pro-ana interaction was positive (β=0.44; P=.003; OR=1.55), showing that mid-scale creators of anti–pro-ana content had greater commenter overlap than expected. The meso-individual×recovery interaction was even stronger (β=0.95; P<.001; OR=2.59), indicating that recovery narratives from meso-level creators act as effective bridges across segmented networks. In contrast, the mega-institution×anti–pro-ana (β=0.40; P=.01; OR=0.67) and mega-individual×anti–pro-ana interactions (β=−0.64; P=.01; OR=0.53) were negative, suggesting that critical content from large channels generated less commenter sharing than predicted.

    In summary, channel type, frame, and their interaction significantly shaped commenter-based intervideo connections. Mega-institutional channels showed high audience overlap, forming dense network regions, whereas meso-individual channels with anti–pro-ana and recovery frames acted as connectors, suggesting alternative diffusion paths. These findings indicate that mid-scale creators occupy strategic positions for exposing advocacy-dominated communities to critical and recovery narratives.

    Principal Findings

    This study examined pro-ana discourse on YouTube within South Korea’s public health context, where adolescent dieting is a major concern. We analyzed how discourse is structured by channel type and framing strategy, and how overlapping commenters influence network cohesion or fragmentation.

    Channels were grouped by ownership and subscriber scale into 6 types, while videos were coded into 3 frames. Analytically, we described framing variation across channel types (RQ1), used SNA to map clustering based on shared commenters (RQ2), and applied the ERGM to test edge formation by frame and channel (RQ3).

    The content analysis showed that pro-ana advocacy frames were concentrated in individual-run channels, particularly meso- and micro-level creators. In contrast, institutional channels—especially those with mega or meso followings—primarily used anti–pro-ana frames stressing health risks and social responsibility. Recovery framing appeared most often in micro-level individual channels, underscoring the need to examine how such narratives spread and connect within the broader video network.

    Network analysis revealed that the video network consisted of multiple tightly knit clusters. Over time, density declined while modularity increased, indicating growing fragmentation. The largest cluster was dominated by pro-ana advocacy videos, whereas anti–pro-ana and recovery content remained peripheral. Cross-frame bridges existed but were limited in both frequency and strength.

    ERGM results showed that institutional channels with mega- or meso-scale audiences were more likely to be linked through shared commenters. Meso-level individual channels, though less connected overall, had significantly higher tie formation when paired with anti–pro-ana or recovery frames. This indicates the potential for bridging discourse clusters, though not causal transmission. Overall, channel type, framing, and their interaction significantly shaped the probability of intervideo connections, highlighting mid-scale individual channels as strategic for spreading health-oriented counter-narratives.

    Together, the 3 analyses provide a multidimensional account of how pro-ana discourse is organized and sustained on YouTube. Videos using critical or recovery frames, when disseminated through meso-level individual channels, emerged as key cross-frame junctures. These channels represent strategic nodes for advancing public health communication.

    Implications

    This study shows that pro-ana discourse on YouTube does not exist within a single open sphere but rather within a fragmented, multilayered ecology shaped by algorithmic curation and selective viewing—a “refracted public” []. Meso- and micro-level individual channels use microcelebrity tactics [] and platform affordances to promote and normalize extreme dieting. These creators generate concentrated volumes of pro-ana content and foster repeated consumption within niche groups, reinforcing discursive insularity. Conversely, institutional channels emphasize recovery narratives and health warnings, but user preferences and recommendation algorithms restrict their diffusion, limiting them to pre-existing audiences.

    Our network analysis using overlapping commenters quantified this segmentation. Rising modularity and declining intercluster connectivity indicate structural limits in linking recovery or critical content with dominant pro-ana clusters. Still, meso-level individual channels emerged as prolific recovery storytellers and bridges for cross-frame commenter overlaps. Their position underscores mid-scale influencers as strategic leverage points for amplifying recovery frame dissemination.

    This study advances health communication research by shifting the focus from institutional campaigns or message content alone to the interplay among user participation, network structure, and channel typology. Prior studies have shown that social media reduces stigma and spreads eating disorder information [,], and influencers can drive positive change [,,]. Our work adds empirical, network-level analysis of how users engage with and circulate pro-ana frames, offering both theoretical and methodological contributions to platform-based health risk communication.

    The Korean context—where thinness ideals are reinforced through fandom, beauty, and fashion content—amplifies the algorithmic visibility of pro-ana discourse. This phenomenon is not unique; similar patterns of esthetic normalization and clustering appear in Western contexts [,], suggesting broader applicability of our findings.

    Practically, this study offers 3 recommendations for public health authorities and digital health communicators. First, rather than relying on blocking harmful content or top-down criticism, emotionally resonant recovery narratives are needed that align with engagement logics inside pro-ana echo chambers. Collaborating with mid-scale creators—especially those sharing recovery experiences—can reduce resistance and increase receptivity [,]. Second, interactive formats that align with YouTube’s affective interface, such as Q&A live streams, recovery-themed challenges, and first-person storytelling, can boost engagement and algorithmic visibility. Third, these strategies extend beyond pro-ana discourse to high-risk contexts like mental health and online extremism, helping transform echo chambers into more interconnected deliberative spaces.

    Limitations

    This study focused only on videos with publicly available comment data to build the commenter-overlap network. As a result, it excluded silent viewing patterns not captured through comments, which may overlook less interactive but influential content. Future research should integrate exposure metrics (eg, views and watch time) with survey or interview data to capture the full spectrum of engagement.

    Another limitation is the lack of reliable demographic data on commenters, restricting assessment of engagement heterogeneity by age, gender, or location and limiting analysis of minority group vulnerability. We also could not confirm whether repeated commenter appearances reflected multiple accounts or bot activity, creating potential bias in interpreting edge density or centrality. This may produce an illusion of inflated interaction around certain channels or frame types, reducing the accuracy of network interpretations. Future research should combine network analysis with qualitative content analysis or targeted interviews to better capture user motivations, identities, and engagement authenticity.

    Conclusions

    This study analyzed the multilayered discursive architecture of pro-ana content on YouTube by examining interactions among channels, frames, and networks. Content analysis showed that advocacy, criticism, and recovery frames varied systematically by channel ownership and subscriber scale. SNA revealed frame-based clustering and growing fragmentation over time. The ERGM estimated conditional probabilities of video-to-video connections based on shared commenters, offering insights into who spreads which messages and how.

    A key finding is that meso-level individual channels, when delivering recovery or critical frames, foster cross-frame overlaps in participation that may disrupt pro-ana echo chambers. Theoretical contributions include: (1) conceptualizing pro-ana discourse as a “fragmented, refracted public” rather than a unified echo chamber, (2) advancing understanding of boundary construction and bridging mechanisms in digital public spheres, and (3) demonstrating the value of combining commenter-overlap network analysis with the ERGM for studying risk communication on digital platforms.

    This study highlights the importance of network-aware health communication strategies that engage mid-scale individual channels as partners in disrupting harmful discourses and amplifying recovery frames. Public health institutions should collaborate with creators to increase message trust and reach while leveraging data-driven targeting to identify and intervene with at-risk groups. Commenter-based network analysis also provides a framework for understanding content flows and designing structural interventions that can open closed communities and promote exposure to health-supportive perspectives.

    We acknowledge the use of ChatGPT (OpenAI) to assist in translating parts of the manuscript from Korean into English. All artificial intelligence–assisted text was reviewed, verified, and edited by the authors, who assume full responsibility for the final content. No external financial, commercial, or institutional support was received for the research, authorship, or publication of this article.

    None declared.

    Edited by Amaryllis Mavragani; submitted 08.May.2025; peer-reviewed by Atte Oksanen, Chun-Hsiang Chan, Ho Young Yoon; accepted 16.Oct.2025; published 04.Nov.2025.

    © Daseul Oh, Shin Haeng Lee. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 4.Nov.2025.

    This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.

    Continue Reading

  • Ontario’s proposed Fighting Delays, Building Faster Act, 2025 and what it means for the development process – Dentons

    1. Ontario’s proposed Fighting Delays, Building Faster Act, 2025 and what it means for the development process  Dentons
    2. From Holdbacks to Terminations: Navigating Bill 60’s Construction Act Amendments  McMillan LLP
    3. Ontario Seeks Public Input on Proposed Official Plan Reforms Under the Fighting Delays, Building Faster Act, 2025  McCarthy Tétrault

    Continue Reading

  • Big Tech Goes to SCOTUS? Google’s Petition in Epic v. Google Makes the Case

    Big Tech Goes to SCOTUS? Google’s Petition in Epic v. Google Makes the Case

    Following the Ninth Circuit’s decision to uphold a series of draconian remedies against Google in the long-running Epic v. Google litigation, Google is now seeking to take its case before the Supreme Court. In a petition filed last week, Google raised a number of important legal questions ripe for the Supreme Court’s consideration—most notably: What should the legal standard be for assessing whether its series of revenue sharing, preinstallation, and distribution agreements were anticompetitive? And did the relief imposed, including a heavy-handed catalog sharing remedy that gives third-party app stores access to Google Play Store’s extensive network of apps, go beyond the scope of proper antitrust relief? These questions are not only critical to resolving Epic v. Google but also implicate similar errors in Judge Mehta’s liability and remedy decisions in the concurrent DOJ v. Google search case.

    The first and most important issue Google raises concerns the rule that was applied to determine whether it acted anticompetitively. Specifically, Google’s practices were evaluated under the rule of reason, which, in its standard formulation as set forth by the Supreme Court in cases like NCAA v. Alston, involves a three-step test: first, the plaintiff presents evidence that the conduct resulted in anticompetitive harm; second, the burden shifts to the defendant to provide a procompetitive justification for its practices; and third, the burden goes back to the plaintiff to show that those benefits could have been achieved through alternatives less restrictive of competition. If the plaintiff can meet its burden at step one and, if necessary, step three, the behavior is anticompetitive and illegal. If not, the defendant wins.

    As Google explains, that’s not what happened here. Rather, the District Court adopted a test in which anticompetitive harms were balanced directly against procompetitive effects, without assessing whether less restrictive alternatives existed. To be sure, courts may allow plaintiffs to prevail under the rule of reason even if they fail the third step of demonstrating the existence of a less restrictive alternative—provided they can prove that anticompetitive harms outweigh procompetitive gains. But this four-step rule of reason is typically applied where the focus is on contractual tying, such as the Ninth Circuit’s County of Tuolumne decision. And while the practice of Google Play Store requiring the use of Google Play Billing for in-app purchases could fall into that bucket, at its core Epic v. Google concerns intrabrand restrictions on Android.

    An analogous mistake with applying the rule of reason can be found in Judge Mehta’s decision in the search case. In holding that Google’s allegedly exclusive default search distribution agreements with third-party browsers, Android OEMs, and wireless carriers were anticompetitive, Judge Mehta laid out the four-step rule of reason described above: first, a plaintiff shows anticompetitive harm; next, a defendant responds by showing procompetitive benefits; and then the burden returns to the plaintiff to show either that there were less restrictive means to achieve those benefits or that they are outweighed by the anticompetitive harms. However, this was the wrong test. Under the U.S. v. Microsoft standard that Judge Mehta applied, there is no room for discounting procompetitive justifications on the grounds that less restrictive alternatives might exist. Indeed, for exclusive dealing generally, a least restrictive alternative analysis is not usually conducted; courts instead simply balance harms against benefits.

    In addition to its concerns with the legal standard applied at the liability phase, Google’s Supreme Court petition in Epic v. Google takes major issue with the catalog sharing remedy imposed upon Google. In general, antitrust remedies—which can take the form of prohibitory injunctions preventing a company from engaging in certain behavior, affirmative obligations requiring a company to take proactive measures, and, in exceptional circumstances, breakups or other structural relief—can serve three purposes: terminating the illegal monopolization, undoing the fruits of the violation, and preventing future anticompetitive practices. Within this scheme, the catalog sharing remedy represents an affirmative obligation for Google to undo the fruits of its statutory violation by giving third-party app stores access to Google Play Store’s catalog of apps. This effectively results in Google losing a key network advantage that makes its Play Store more attractive to users: a greater catalog of apps.

    But in upholding this remedy as a “‘reasonable method’ of counteracting the Play Store’s dominance and reducing the network effects it enjoys by temporarily lowering barriers to entry,” the Ninth Circuit seems to have erred. Specifically, the “reasonable method” standard set forth by the Supreme Court in Nat’l Soc’y Professional Engineers applies either to, as in that case, prohibitory injunctions to undo the fruits of anticompetitive behavior or, as the Massachusetts v. Microsoft case made clear, affirmative obligations designed to terminate the anticompetitive effects of the illegal monopoly. It should not apply to affirmative obligations intended to deny the fruits of anticompetitive behavior, which, as the latter court explained, require a higher standard mandating that “the fruits of a violation must be identified before they may be denied.” Yet the catalog sharing remedy makes no effort to distinguish between app network effects achieved through anticompetitive versus procompetitive means.

    This error is repeated in the relief approved by Judge Mehta in the Google search case. Specifically, while rightly rejecting the DOJ’s radical proposal to force Google to divest Chrome and potentially Android, Judge Mehta similarly imposed a series of data sharing remedies that, as he made clear, “are designed primarily to deny Google a key fruit of its anticompetitive conduct—scale—and to help rivals overcome that deficit.” In particular, Judge Mehta required Google to share certain search index and user-interaction data with competitors to help improve their own search services. However, like the Ninth Circuit, Judge Mehta merely asked whether this relief was a “reasonable method of eliminating the consequences of the illegal conduct,” rather than precisely identifying which data constituted the fruits of Google’s anticompetitive behavior, as opposed to data Google obtained through the normal, procompetitive operation of its search service.

    The Supreme Court doesn’t take many cases a year, and major antitrust decisions from the Court, as this one would be, are always quite rare. However, amidst the number of landmark antitrust cases against Big Tech companies that will, whichever way they are decided, have huge implications both for antitrust law and the American economy, the Epic v. Google case presents a unique opportunity for the Supreme Court to head off potential legal confusion by providing necessary guidance in two key areas where Judge Mehta in the Google search case also appears to have erred. Specifically, by clarifying which version of the rule of reason applies to different forms of conduct and what level of scrutiny should govern affirmative obligation remedies intended to divest the fruits of anticompetitive behavior, the Court can lay out a much-needed framework to guide lower courts as they adjudicate these once-in-a-generation antitrust actions against Big Tech.

    Continue Reading

  • Tangerine and Engine by Starling sign agreement to provide next generation banking for millions of Canadians

    Tangerine and Engine by Starling sign agreement to provide next generation banking for millions of Canadians

    Engine to provide complete digital banking platform for 2+ million Tangerine clients in Canada

    TORONTO and LONDON, Nov. 4, 2025 /PRNewswire/ — Tangerine Bank (Canada’s award-winning digital bank and wholly-owned subsidiary of Scotiabank, one of the “Big 5” banks in Canada with assets of approximately $1.4 trillion) and Engine by Starling (the Starling Group’s banking Software-as-a-Service (SaaS) business) today announced an agreement to deliver a next-generation banking platform for more than 2 million Tangerine clients in Canada.

    Under the terms of the 10-year agreement, Tangerine will upgrade its core digital banking system to Engine’s cloud-native banking platform, enabling the digital bank to supercharge its client experience and embark on an ambitious new phase of growth.

    With Engine’s SaaS platform, Tangerine’s clients will experience best in class digital onboarding, chequing accounts, instant access savings, overdrafts, debit cards and smart money management features such as card controls and spending insights, delivered through an intuitive mobile app. Behind the scenes, Engine’s end-to-end platform will provide a simplified account view and consolidate the capabilities and support tools Tangerine needs to reduce operational cost and complexity for employees.

    Tangerine becomes Engine’s first North American client after the British firm announced offices in New York and Toronto earlier this year. Born of the UK’s Starling Bank in 2022, the company currently supports Salt Bank in Romania and AMP Bank GO in Australia.

    Terri-Lee Weeks, President and CEO of Tangerine, said: “Tangerine chose Engine to help build the future of banking services for our clients – delivering a premier banking experience with intuitive, personalized features that evolve with client needs. Engine’s modern core banking system uniquely provides an end-to-end platform on which Tangerine can innovate quickly and continuously, reducing the time-to-market for new products and features, and delivering world-class experiences for our clients – all while staying true to the client-first design that Tangerine is known for in Canada.”

    Sam Everington, CEO of Engine by Starling, added: “Engine’s technology and operating model is a tried and tested blueprint for building market-leading digitally-native banks. It is a true fintech success story as we see our software enabling ambitious, innovative and customer-centric banks all over the world. This agreement with Tangerine is a major milestone and the largest deal we have signed to date, showing just how scalable and adaptable Engine is.”

    This announcement follows Engine’s expansion into the North American market to support its global growth and to develop new capabilities. Tangerine will benefit from a dedicated Engine team in Toronto consisting of product, delivery and technical specialists, who will now collaborate to deliver a refreshed suite of digital features and services.

    About Tangerine Bank:

    Tangerine is one of Canada’s leading digital banks, empowering over two million clients to reach their goals and move their finances forward. Known for a simple-to-use digital and mobile experience, Tangerine offers everyday banking products without any complicated hoops to jump through. From saving and spending to investing and borrowing, Tangerine’s products are designed to meet the unique needs of Canadians. Tangerine’s commitment to putting clients first has earned the bank recognition as the #1 Bank in Canada by Forbes in 2025 and the most awarded midsize Bank by the J.D. Power Canada Retail Banking Satisfaction Study for 14 consecutive years as of 2025**. Tangerine Bank was launched as ING DIRECT Canada in 1997. In 2012, Tangerine was acquired by Scotiabank and operates independently as a wholly owned subsidiary. Tangerine is a registered trademark of The Bank of Nova Scotia, used under license.

    For more information, visit tangerine.ca or connect with us on social on Instagram, LinkedIn, or TikTok.

    About Engine by Starling
    Engine by Starling is a SaaS technology provider with the goal of bringing its modern banking platform to banks around the world. The Engine platform, built to power Starling in the UK, is modular, API-based, cloud-native and a proven technology at scale.

    For further information about Engine by Starling, please visit: enginebystarling.com

    About Starling Group
    Starling Group includes Starling Bank, the fully licensed and regulated UK bank, Engine by Starling, a Software-as-a-Service (SaaS) provider, and Fleet Mortgages, a specialist Buy-to-Let mortgage lender. Headquartered in London, the Group has offices in Cardiff, Manchester and Southampton.

    Photo – https://mma.prnewswire.com/media/2813535/Tangerine_Tangerine_and_Engine_by_Starling_sign_agreement_to_pro.jpg 
    Logo – https://mma.prnewswire.com/media/2813537/Tangerine_Tangerine_and_Engine_by_Starling_sign_agreement_to_pro.jpg


    Continue Reading